Exelixis Gains 15.6% YTD: How Should You Play the Stock?

Key Takeaways Cabometyx sales grow with strong RCC demand and new NET label expansion. Zanzalintinib combo met a key endpoint in the STELLAR-303 CRC study.Q2 revenue miss and RCC competition weigh on EXEL's near-term outlook.Exelixis’ (EXEL) year-to-date performance has been good. Shares of the biotech company have gained 15.6% compared with the industry’s growth of 2.9%. While shares hit a 52-week high of $49.62 on June 23, 2025, it dipped after the company reported second-quarter results on July 28.Noneth ...